Home

Wednesday, 1 October 2025

Prostate Cancer Biomarkers Market To Reach $9.8 Billion By 2030

 

Prostate Cancer Biomarkers Market Growth & Trends

The global prostate cancer biomarkers market size is expected to reach USD 9.8 billion by 2030, registering a CAGR of 13.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is undergoing rapid evolution driven by the increasing demand for precision diagnostics and the limitations of conventional screening methods like PSA testing. PSA, while widely used, has low specificity, often leading to overdiagnosis and overtreatment. As a result, there is a significant shift towards molecular and genomic biomarkers that can offer improved diagnostic accuracy and guide clinical decisions. Emerging biomarkers such as PCA3 (Prostate Cancer Antigen 3), 4Kscore, and ConfirmMDx have demonstrated superior performance in risk stratification and biopsy decision support. These tests are increasingly being integrated into clinical practice to reduce unnecessary biopsies and improve patient outcomes.

A key market driver is the growing focus on personalized medicine. Genomic classifiers like Decipher and Oncotype DX GPS help determine the aggressiveness of prostate tumors and inform treatment planning, especially in early-stage patients deciding between active surveillance and intervention. Liquid biopsy-based technologies are also gaining attention for their non-invasive nature, with urine-based tests like SelectMDx and ExoDx offering clinically actionable insights for patients with elevated PSA. These innovations are particularly relevant in cases where traditional biopsies carry risks or yield inconclusive results.

Technological advancements in next-generation sequencing (NGS) and transcriptomics are further accelerating biomarker discovery. For example, studies have identified gene fusions such as TMPRSS2-ERG and mutations in BRCA1/2 and ATM as significant markers for prognosis and therapeutic guidance. The increasing use of these biomarkers in selecting patients for targeted therapies like PARP inhibitors reflects the rising importance of companion diagnostics in the treatment ecosystem. Moreover, metabolomic biomarkers, which analyze small-molecule metabolic changes associated with tumor progression, are emerging as promising tools for early detection and monitoring.

However, the market still faces several challenges. Standardization across biomarker assays remains limited, and there is a lack of consensus among clinicians regarding which tests to adopt and at what clinical stages. Reimbursement issues and cost concerns can hinder the routine use of advanced biomarker tests, particularly in regions with constrained healthcare budgets. Furthermore, regulatory pathways for biomarker approval are often lengthy, which can delay commercial availability. Even as newer tests enter the market, widespread clinical adoption requires large-scale validation studies and integration into existing clinical workflows.

Despite these barriers, the prostate cancer biomarker industry presents notable growth opportunities. Collaborations between academia and industry are intensifying, aimed at discovering and validating novel biomarker panels. With increasing awareness of the limitations of PSA and growing emphasis on value-based care, there is strong momentum to shift toward more informative, less invasive diagnostics. In this context, biomarkers like AR-V7, used for monitoring treatment resistance in advanced prostate cancer, illustrate the potential of biomarker-guided therapy selection.

As the field continues to advance, prostate cancer diagnostics are moving toward a more integrated and individualized model, where molecular insights guide not only early detection but also therapeutic decisions and long-term management strategies.

Some of the key players in the market are Exact Sciences, Myriad Genetics, Bio-Techne, Olympus Corporation, OPKO Health. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in December 2024, Myriad Genetics’ Prolaris test continues to be recognized by the National Comprehensive Cancer Network (NCCN) as an Advanced Tool for prostate cancer prognosis. It remains included in the NCCN guidelines with a Category 2A evidence level, indicating strong support (≥85%) from the NCCN prostate panel. This classification reinforces Prolaris’ clinical relevance in helping guide treatment decisions based on tumor aggressiveness.

Request a free sample copy or view report summary:
Prostate Cancer Biomarkers Market Report

Prostate Cancer Biomarker Market Report Highlights

Prostate Cancer Biomarker Market Segmentation

Grand View Research has segmented the global prostate cancer biomarker market based on type, application, end-use, and region:

Prostate Cancer Biomarker Type Outlook (Revenue, USD Million; 2018 - 2030)

Prostate Cancer Biomarker Application Outlook (Revenue, USD Million; 2018 - 2030)

Prostate Cancer Biomarker End-use Outlook (Revenue, USD Million; 2018 - 2030)

Germany Health Insurance Market Size (GWP) To Reach $529.70 Billion By 2030

 

Germany Health Insurance Market Growth & Trends

The Germany health insurance market size in terms of GWP market size is expected to reach USD 529.70 billion by 2030, registering a CAGR of 5.30% from 2025 to 2030, according to a new report by Grand View Research, Inc.

The increasing aging population in Germany is one of the key drivers contributing to the market growth. As Germany experiences a demographic shift, with a rising number of individuals aged 65 and above, the demand for comprehensive healthcare services is increasing. For instance, the AARP International report indicates that Germany’s population aged 65 and above is expected to increase by 41 percent, reaching 24 million by 2050, which will make up almost one-third of the overall population. This demographic shift has increased the demand for medical services, long-term care, and chronic disease management. As a result, health insurers are expanding their coverage options to meet the needs of the growing elderly population.

Moreover, the increasing proportion of high-income individuals in Germany is anticipated to positively influence the growth of the private health insurance segment. According to data published by GermanPedia in 2025, the top 1% of earners in Germany had a gross annual income exceeding USD 275,248 in 2023, while approximately 15% of the population earned over USD 77,069 annually. This demographic segment typically demonstrates a higher propensity to choose premium private health insurance offerings due to their preference for comprehensive coverage options, quicker access to healthcare services, and personalized medical care. Consequently, this trend is expected to further drive the expansion of the private health insurance market in Germany.

Some of the key players in the market are Allianz SE, Debeka Krankenversicherungsvere A.G., Generali Deutschland, R+V Versicherung AG, AXA Konzern AG, ERGO, Techniker Krankenkasse (TK), BARMER, DKV Deutsche Krankenversicherung, Signal Iduna. Players are adopting key strategic initiatives to expand their business footprint and grow their clientele. For instance, in February 2024, AXA announced its strategic plan "Unlock the Future" for 2024-2026, setting ambitious financial targets. The plan focuses on leveraging AXA's market-leading position and a robust balance sheet to drive revenue growth and meet financial objectives. By prioritizing innovation, digital transformation, and targeted expansion, this strategy is expected to enhance AXA’s competitive edge and drive growth in Germany’s health insurance market.

Request a free sample copy or view report summary:
Germany Health Insurance Market Report

Germany Health Insurance Market Report Highlights

Germany Health Insurance Market Segmentation

Grand View Research has segmented the Germany health insurance market on the basis of insurance type, policy type, and distribution channel:

Germany Health Insurance Type Outlook (Revenue USD Billion, 2018 - 2030)

Germany Health Insurance (GWP) Policy Type Outlook (Revenue USD Billion, 2018 - 2030)

List of Key Players in Germany Health Insurance Market